trending Market Intelligence /marketintelligence/en/news-insights/trending/muw4z0m4t6r-nqbb3ovlrg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche, Exelixis' Tecentriq combo fails in late stage colorectal cancer study

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Roche, Exelixis' Tecentriq combo fails in late stage colorectal cancer study

Roche Holding AG said a late stage trial of its cancer drug Tecentriq, combined with Exelixis Inc.'s Cotellic, in a type of colorectal cancer failed to meet its main goal.

Statistically significant results from a phase 3 study, dubbed IMblaze370, did not help patients live longer with the disease compared to Bayer AG's Stivarga.

The study evaluated previously treated patients with difficult-to-treat colorectal cancer that has grown outside the organ or has spread across the body. The patients were either intolerant to at least two systemic chemotherapy regimens or had their disease progress after the chemotherapy treatments.

Tecentriq is part of a class of immune system-boosting drugs known as checkpoint inhibitors. Inhibitor drugs target immune checkpoints such as PD-L1 and CTLA-4 to prevent cancer cells from downregulating and hiding from the body's immune system.

SNL Image

The Swiss drugmaker said over 95% of patients in the IMblaze370 trial have microsatellite stable tumors — cancers with chromosomal instability and are harder to cure. Available data suggests that checkpoint inhibitors as single treatments have not shown efficacy for these types of tumors.

Cotellic, also known cobimetinib, is being developed under a worldwide collaboration agreement between California-based Exelixis and Genentech Inc., a unit of Roche.

Roche is studying Tecentriq, both as a single therapy and in combination with other drugs, for treating lung, bladder, kidney, skin and breast cancers, among other indications.